ERBB2 and breast cancer: Along with trastuzumab, various anti-HER2 monoclonal antibodies, including afatinib, gefitinib, neratinib, or lapatinib, individually or in conjunction with standard therapies, have helped to expand the range of therapeutic choices available to breast cancer patients.